Northwest Therapeutics seeks additional financing
This article was originally published in Scrip
Northwest Biotherapeutics hopes to secure more funding to see it through the next two months. The US company, listed on London's AIM, says that it is in advanced stages of negotiations and expects to make an announcement shortly. It would not disclose the amount it needed, but said it might not be able to continue operations if it failed to obtain the funding. Northwest, which develops immunologicals to treat cancers more effectively than existing products, revealed in August that it had a severe shortage of cash (Scrip Online, August 21st, 2008).
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.